Bamco Inc. NY Acquires 8,500 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Bamco Inc. NY lifted its holdings in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 2.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 347,800 shares of the company's stock after purchasing an additional 8,500 shares during the period. Bamco Inc. NY owned about 1.16% of Inspire Medical Systems worth $64,475,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. First Horizon Advisors Inc. increased its position in shares of Inspire Medical Systems by 885.7% during the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock worth $26,000 after purchasing an additional 124 shares in the last quarter. Huntington National Bank boosted its stake in shares of Inspire Medical Systems by 228.3% in the fourth quarter. Huntington National Bank now owns 174 shares of the company's stock worth $32,000 after buying an additional 121 shares during the last quarter. Harbour Investments Inc. raised its position in Inspire Medical Systems by 101.0% during the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company's stock valued at $37,000 after acquiring an additional 99 shares in the last quarter. AlphaQuest LLC boosted its holdings in Inspire Medical Systems by 7,275.0% during the fourth quarter. AlphaQuest LLC now owns 295 shares of the company's stock worth $55,000 after buying an additional 291 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its stake in shares of Inspire Medical Systems by 61.9% during the 4th quarter. Quadrant Capital Group LLC now owns 327 shares of the company's stock worth $61,000 after buying an additional 125 shares during the period. Institutional investors own 94.91% of the company's stock.

Insider Buying and Selling

In other Inspire Medical Systems news, Director Shawn Mccormick sold 360 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $160.00, for a total value of $57,600.00. Following the sale, the director now owns 24,046 shares of the company's stock, valued at $3,847,360. The trade was a 1.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Randy Ban sold 25,584 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the completion of the sale, the insider now owns 7,259 shares in the company, valued at $1,332,026.50. This represents a 77.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,527 shares of company stock valued at $4,851,660 over the last three months. Company insiders own 4.10% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on INSP shares. Royal Bank of Canada decreased their target price on Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 15th. Piper Sandler dropped their target price on shares of Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating for the company in a report on Monday, February 10th. KeyCorp dropped their price objective on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating for the company in a report on Monday, April 21st. Stifel Nicolaus dropped their price objective on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a research report on Monday, April 21st. Finally, JPMorgan Chase & Co. dropped their target price on shares of Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating on the stock in a research report on Tuesday. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $211.91.

Inspire Medical Systems Stock Down 0.6 %

Shares of INSP traded down $0.91 during mid-day trading on Friday, hitting $151.88. The stock had a trading volume of 156,626 shares, compared to its average volume of 534,664. The company has a market cap of $4.48 billion, a PE ratio of 87.79, a PEG ratio of 2.86 and a beta of 1.39. Inspire Medical Systems, Inc. has a fifty-two week low of $123.00 and a fifty-two week high of $225.00. The company's fifty day simple moving average is $158.28 and its two-hundred day simple moving average is $178.63.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.33. The firm had revenue of $201.32 million for the quarter, compared to analyst estimates of $194.89 million. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. The firm's revenue for the quarter was up 22.7% on a year-over-year basis. During the same period last year, the company earned ($0.34) earnings per share. Equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.